Safety and efficacy of the Mynx Control vascular closure device in peripheral arterial procedures: A prospective study. (April 2023)

• Record Type: Journal Article
• Authors: Diamantopoulos, Athanasios; Nourzaie, Romman; Mulholland, Doug; Dolan, Steven G; Ahmed, Irfan; Gkoutzios, Panos; Thulasidasan, Narayanan; Theodoulou, Iakovos; Sabharwal, Tarun
• Is Part Of: Vascular. Volume 31:Number 2(2023)
• Page Start: 369
• Page End: 374
• Publication Date: 2023-04
• Subjects: Mynx Control -- vascular closure device -- manual compression -- peripheral arterial disease -- radiology -- interventional radiology; 616.13
• DOI: 10.1177/17085381211062745
• Languages: English
• ISSNs: 1708-5381

Abstract

Objectives: This article aims to present a prospective study investigating the safety and efficacy of the Mynx Control extravascular closure device (Cordis Corporation, FL, USA), for femoral arterial closure in patients undergoing peripheral arterial procedures. Methods: Between January 2020 and February 2021, 100 Mynx Control devices were deployed in 91 consecutive patients (mean age: 67.5 ± 16.9 years) who underwent peripheral arterial procedures. We used ultrasound and/or fluoroscopy during Mynx Control deployment and ultrasound post-procedure to detect complications. Femoral artery punctures included 62 (62%) antegrade and 38 (38%) retrograde punctures. The mean activated clotting time at time of device deployment was 221s. The primary endpoints were technical success, device failure, and complication rates up to 30 days. Results: A 5F vascular sheath was used in 43 cases (43%) (36 (36%) 6F and 21 (21%) 7F). The majority of our cases had antegrade access (62%). Overall technical success rate was 97% in both antegrade and retrograde cases. In total, there were 4 minor complications: 3 (3%) cases of pseudoaneurysm and 1 (1%) case of haematoma. No major complications were recorded post-procedure or 30 days post index procedure. Conclusion: The Mynx Control vascular closure device is safe and effective in achieving haemostasis in patients undergoing antegrade and retrograde peripheral angioplasty procedures.